Effects
From Evidence to Action: What Works Against AMR
Countries around the world have made significant progress in developing National Action Plans on antimicrobial resistance. But progress on paper and progress in practice are not always the same. Many countries face an implementation gap — plans exist, but translating them into sustained, system-wide action remains difficult.
The good news is that we are not starting from scratch. There is now clear, global evidence on what works. This page distills that evidence into five practical areas of action.
Article libraryA System Challenge, Not a Single Intervention
AMR is not driven by one factor, and there is no single solution. Effective responses share a common characteristic: they combine clinical, public health, agricultural, and policy interventions under a coordinated One Health approach.
Rather than isolated activities, impact comes from packages of interventions working together. Countries that have made the greatest progress are those that have addressed multiple drivers of AMR simultaneously — across sectors, systems, and levels of government.
The Five Core Areas of Effective Action
Across countries and settings, five areas consistently emerge as the most impactful. Each is well-evidenced, practically implementable, and mutually reinforcing when combined with the others.
Smarter Use of Antibiotics in Healthcare
Antimicrobial stewardship ensures antibiotics are used only when needed, and in the right way. These are often simple changes — but they have a high impact on both patient outcomes and resistance levels.
- Reviewing prescriptions and providing clinician feedback
- Adjusting treatments based on laboratory results
- Switching from intravenous to oral treatment when possible
Preventing Infections Before They Occur
The most effective way to reduce antibiotic use is to reduce infections. Infection prevention and control (IPC) measures are among the most cost-effective interventions available.
- Hand hygiene and safe patient care
- Clean clinical environments
- Isolation and containment of resistant organisms
Investing in Public Health Foundations
AMR is deeply connected to broader system conditions. Access to clean water, sanitation, and hygiene (WASH) and strong vaccination programmes play a critical role in reducing infections at population level.
- Lower overall need for antibiotics
- Prevent resistant infections before they emerge
- Deliver benefits far beyond AMR alone
Addressing Use in Agriculture and Food Systems
Globally, a large proportion of antimicrobials are used in animals. Countries that have acted in this sector demonstrate that reductions are achievable without compromising productivity.
- Phasing out antibiotics for growth promotion
- Improving farm hygiene and biosecurity
- Strengthening veterinary oversight and regulation
Enabling Action Through Policy and Governance
None of the above works at scale without strong governance. Governance is what turns technical solutions into system-wide, sustained impact.
- Clear national coordination mechanisms
- Enforced regulations on antibiotic use
- Functional surveillance systems
- Alignment across human, animal, and environmental sectors
How These Interventions Work Together
Rather than acting independently, these five areas reinforce each other. The most successful strategies combine them into coherent national programmes, rather than prioritizing one in isolation. The table below summarises how each area contributes to the overall response.
| Area | Primary effect | System impact |
|---|---|---|
| Stewardship (AMS) | Reduces inappropriate use | Improves clinical outcomes and slows resistance |
| Infection prevention (IPC) | Prevents transmission | Reduces infections and hospital burden |
| WASH & vaccination | Prevents disease | Lowers antibiotic demand at population level |
| Agriculture | Reduces non-human use | Limits spread through food systems and the environment |
| Governance | Enables coordination | Ensures sustainability, scale, and cross-sector alignment |
The Economic Argument Is Clear
AMR is not only a health issue — it is a major economic risk. Without action, the global cost is projected to reach trillions annually in lost productivity, increased healthcare spending, and broader societal disruption. At the same time, evidence consistently shows that investing in combined interventions yields very high returns.
Source: WOAH / CGD / IHME EcoAMR Series (2024)
Source: Center for Global Development, EcoAMR (2024)
Source: Karanika et al., Antimicrobial Agents and Chemotherapy (2016) & Painter et al., AMR & Infection Control (2023)
The economic case is straightforward: inaction is costly, action is cost-effective, and well-designed packages of interventions deliver strong returns — both in health outcomes and in economic terms.
This makes the argument for investment not just a moral one, but a financial one that ministries of finance and development partners can engage with directly.
What This Means in Practice
The evidence does not point to complex or experimental solutions. Instead, it highlights proven, practical interventions that can be adapted to different country contexts, health systems, and levels of AMR NAP maturity.
The real challenge is not identifying what to do — it is prioritizing the right actions, adapting them to country realities, and implementing them consistently over time. This requires structure, facilitation, financing, and continuous learning from experience.
For countries working on or updating a National Action Plan, the key question is not “What should we do?” — but rather “How do we make this work in our system?”
Ready to Translate Evidence into Action?
Whether you are developing a new NAP, costing an existing plan, or building a case for investment, structured support is available to help you apply this evidence in your country context.